Goldman Sachs Group Inc Oncternal Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.83 - $17.8 $146,472 - $3.14 Million	-176,473 Reduced 93.06%	13,161 $12,000
Q3 2022 Nov 10, 2022	SELL	$0.83 - $17.8 $146,472 - $3.14 Million	-176,473 Reduced 93.06%	13,161 $0
Q2 2022 May 14, 2024	BUY	$0.7 - $1.56 $132,743 - $295,829	189,634 New	189,634 $211,000
Q2 2022 Aug 15, 2022	BUY	$0.7 - $1.56 $15,249 - $33,984	21,785 Added 12.98%	189,634 $211,000
Q1 2022 May 16, 2022	BUY	$1.37 - $2.43 $1,124 - $1,995	821 Added 0.49%	167,849 $233,000
Q4 2021 Feb 14, 2022	BUY	$2.27 - $4.39 $143,123 - $276,789	63,050 Added 60.64%	167,028 $379,000
Q3 2021 Nov 10, 2021	BUY	$3.37 - $4.76 $350,405 - $494,935	103,978 New	103,978 $434,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.